I am looking for dividend stocks to increase the payout for the months of January, July and October, does anyone have any suggestions that might fit my portfolio? Would also like to $NOVO B (+0,04%) get rid soon and invest in another stock in the healthcare industry.

Handelsblatt searched the Dax, Stoxx 50 and Dow Jones for so-called quality stocks that are undervalued - i.e. whose price level is lower than the long-term average.

In order to be selected as a quality stock, the companies must have consistently fulfilled five conditions over the past five years:

• Rising or at least stable earnings before interest and taxes (EBIT),
• high liquid funds from the core business (operating cash flow) to cover ongoing costs at all times,
• low to moderate net debt in relation to equity; well below 100 percent,
• Rising dividends year after year,
• lower valuation than the company's own ten-year average - calculated from the ratio of consolidated earnings to market capitalization.

The sharp rise in share prices in recent years means that only five out of a total of 120 companies listed on the Dow, Stoxx and Dax fulfill all five conditions. Only one stock from the leading German index is included.

Visa $V (+0,04%): The moat stock is available with a six percent valuation discount

Current dividend yield: 0.8%

Several million merchants worldwide accept payments in supermarkets, when shopping online or when traveling abroad. More than half of the group's revenues remain as profit, making Visa one of the most profitable companies worldwide and at the same time a typical moat share.

Higher prices and thus inflation have a positive effect, as they mean higher revenues for Visa because the credit card fees are linked to the merchant's turnover as a percentage.

L'Oréal $OR (-1,7%): Ten percent valuation discount and the Group is growing faster than the market

Current dividend yield: 1.9%

When the world's largest cosmetics manufacturer reported sales growth of 4.2 percent in the past quarter, the share was one of the biggest losers of the day. Analysts had expected more. The share is trading 20 percent below its record high.

According to analysts' average forecasts, L'Oréal should earn 6.7 billion euros before interest and taxes in the current full year. That would be more than ever before and almost twice as much as five years ago. In the same period, the dividend per share rose from 3.85 euros to seven euros.

With a P/E ratio of 27.4 based on the earnings forecast for the next four quarters, the share is valued ten percent lower than its ten-year average.

Procter & Gamble $PG (-0,65%): The dividend is safe and always rising

Current dividend yield: 2.9%

Branded products such as Ariel, Pampers, Braun and Gillette provide the American consumer goods manufacturer with reliably rising earnings. Over the past five years, earnings before interest and taxes have risen by 23%.

However, this year has shown that even such defensive shares are not resistant to price losses. Procter & Gamble is currently trading just under 20 percent below the record high it reached twelve months ago.

There are two reasons for this: the preference of many investors for more speculative technology shares, but also higher financial burdens for many consumers due to the rising cost of living. As a result, more consumers preferred cheaper own brands from retailers such as Walmart in the USA or Edeka and Rewe in Germany.

In the long history of the stock market, such price setbacks have almost always proved to be good opportunities to enter the market. The share is currently valued at a P/E ratio of 20.8 based on the earnings forecast for the next four quarters. This is seven percent below the average of the past ten years - after P&G had been valued above the historical average in recent years.

The strongest argument is probably the profit distributions. The Group has paid dividends every year since 1890. Since the end of the 1950s, Procter & Gamble has increased its dividend every year. Around 50 percent of profits go to shareholders.

This leaves enough of a buffer to increase the dividend even in years with slightly falling profits. Over the past five years, the dividend has risen by around one euro to 3.75 euros per share.

German Stock Exchange $DB1 (-0,76%): Not only the stock market business drives profits

Current dividend yield: 1.8%

The Frankfurt stock exchange operator is set for its seventh record profit year in a row in 2025. In the third quarter, net revenue, pre-tax profits and earnings per share continued to rise as usual. Nevertheless, the share, which has risen sharply in recent years, has come under pressure in recent months: down 25% since the beginning of May.

Deutsche Börse is currently negotiating the purchase of the fund management platform Allfunds for 5.3 billion euros. Allfunds offers fund managers and distributors a platform for trading, data analysis and compliance systems.

The result of so much consistency is reliable dividends: The dividend has risen for nine years in a row, and the tenth increase is due next spring.

In view of the recent share price losses - coupled with rising consolidated profits - the share is no longer overvalued after a long time. With a P/E ratio of 18.7 based on the expected profits in the next four quarters, the share is valued three percent lower than its ten-year average.

Novo-Nordisk $NOVO B (+0,04%): Highest valuation discount and highly speculative

Current dividend yield: 3.8%

The most speculative share among the stocks portrayed here is Novo Nordisk. With the presentation of its third-quarter results, the Danish pharmaceutical group once again lowered its sales and earnings targets. In addition, the management, under its new CEO since August, Maziar Mike Doustdar, cut its investment plans.

The company had grown strongly with the sales injection Wegovy, which had made Novo Nordisk the most valuable stock market group in Europe for a time, before competitors, above all the US group Eli Lilly $LLY (-0,45%)successfully competed with similar products. Mass redundancies at Novo Nordisk were the result.

Despite all the setbacks, the pharmaceutical company is still increasing its profits - but at a slower rate. In the current year, analysts are forecasting average earnings before interest and taxes of the equivalent of 14.1 billion euros, compared to 13.5 billion euros in the previous year.

Since last summer's record high, the share price has fallen by 70 percent. This constellation - rising profits, collapsing share price - makes the once very highly valued share with a P/E ratio of 12.9 suddenly inexpensive. The ten-year average is almost twice as high with a P/E ratio of 23.4. No other quality share is currently trading at such a high valuation discount.

Novo Nordisk recently achieved positive results in tests with the drug Amycretin in diabetes patients. According to the company, these patients reduced their weight considerably and were also able to significantly lower their blood sugar levels.

This was Novo Nordisk's core business before the hype surrounding weight loss injections began. Over the past 30 years, the number of diabetics worldwide has quadrupled to around half a billion. According to the market research institute Mordor Intelligence, the Group has a 45 to 50 percent share of insulin products, making it the undisputed global market leader.

Source text (excerpt) & image, Handelsblatt 01.12.25

November was once again a classic "rollercoaster month" - with a fortunately positive outcome. We started with a portfolio performance of -3% and then rose to +5% in the middle, then fell again to -2% and closed the month with around +8%! For the portfolio, this means that we have reached a new all-time high! 👍🏼

Start: 1,148,200 euros

End: 1,253,497 euros + 19,000 cash

Deposit: 30,000 euros

Profit: +94,297 euros (+8.2%)

Once again this month (as in October), my two gold positions were mainly responsible for the volatility, as they now account for 44% of my portfolio - but hey, I'm still convinced that there's a lot of potential in these stocks. So the rollercoaster will continue... 🎢

One of my less heavily weighted mining stocks, $SCZ (+1,08%) SantaCruz Silver Mining, I sold completely on Friday after disappointing quarterly figures. Although the share is being driven by the strong silver price, this can quickly go in the other direction if the support falls away. The bottom line was a gain of +12% after only 6 weeks. We can be satisfied with that. I only have a total of 4 mines left in my portfolio: $KNT (-0,22%)
$EQX (+0,71%)
$BTO (+0,31%) and $ESM (-0,78%) .

Otherwise, I used the month to buy stocks that had fallen out of favor but that I am still convinced of. These include $PYPL (+0,31%)
$NOVO B (+0,04%)
$1810 (-1,27%) (Xiaomi) $GLJ (-1,33%) (Grenke), $LXS (-0,5%) and $EVK (-1,15%) have been. Novo-Nordirsk in particular presented a great opportunity a few days ago when the share price briefly plummeted by 10% without justification. 📉

At the same time, I was also able to realize a few profits. I took the opportunity to sell some of my Puma shares after the takeover rumors and at the beginning of the month I also sold Lufthansa, BHP Billiton and a small amount of Western Union (which has already been bought back at a lower price). 📈

I currently hold 19,000 euros in cash again and am waiting for the next opportunities! 💵

➡️🆓: On my way towards 4 million total assets, the target achievement rate is now 42.3%. 😊

Let's see how November turns out. As always, it remains exciting!

Hello everyone,

in order to reduce my buyin, I have once again added a lot of $NOVO B (+0,04%) again.

$NOVO B (+0,04%) 🙈

$NOVO B (+0,04%) is lagging far behind its American competitor $LLY (-0,45%) Is the hoped-for turnaround coming now?

In the brief analysis you will find the latest news, the fundamental analysis and the technical outlook:

https://investment-traders.com/kurzanalysen/novo-nordsik-aktie---top-meldung-turnaround

The US government has negotiated a maximum price for semaglutide products (Ozempic, Wegovy, Rybelsus) that will apply to the government Medicare Part D program from January 1, 2027.

The negotiated price reduces the list price by up to 71 %. $NOVO B (+0,04%) However, the government already grants health insurers high discounts and rebates on the actual net sales price for Medicare Part D.

Novo Nordisk expects the maximum prices for Ozempic, Rybelsus and Wegovy (in Medicare Part D) effective from January 2027 to have a low single-digit negative impact on global sales growth for 2027. Medicare Part D sales are significant (in 2022 it was $5.57bn, I have not found more recent figures). In relation to the total global sales generated by GLP-1 drugs (especially Wegovy in the commercial market), the growth potential should not be fundamentally impaired.

The long-term growth story of GLP-1 drugs (diabetes, obesity and new indications) remains the dominant value driver.

Despite the short-term share price turbulence and the regulatory hurdles in the USA, Novo Nordisk remains an attractive growth stock in the pharmaceutical sector for me. I sold some of my shares (50 units) some time ago and have since put them back in the portfolio. Currently standing at 10% p.a. since 2015 with $NOVO B (+0,04%)

https://www.cms.gov/files/document/infographic-negotiated-prices-ipay-2027.pdf

Hi,

I've been reading posts here for weeks about $NOVO B (+0,04%) which are almost religious in nature - it feels like 90% of the posts are either putting the company down or praising it to the skies - the remaining 10% are informative reports .....

Everyone makes their own decisions and investing money in individual shares can always go both ways ...... I myself bought 15 shares at a price of around €52 and another 15 shares at €37. Of course, both points of view can come into play here too:

• uhhh - reach into a falling knife
• ohhh - take advantage of favorable prices

I feel the same way as everyone here and as Einstein once said so aptly: forecasts are a difficult thing, especially when they concern the future .... My average purchase price is € 44.90 - if the price rises above that - fine. If not - bad luck :-) But where the price will be in February 2026 ( as an example ) : no idea .... and I share that with everyone here :-)

After $NOVO B (+0,04%)
caused a disappointment in Alzheimer's research at the beginning of the week, the company is now back in the headlines - but this time in a positive light. On Tuesday, the Danes reported convincing results from the phase 2 trial with the active ingredient Amycretin in type 2 diabetes patients. All losses from the beginning of the week have now almost been made up.

According to the company, the participants achieved a significant weight reduction of up to 14.5 percent within 36 weeks. At the same time, blood glucose levels also improved measurably: around 89 percent of the test subjects achieved an HbA1c value below seven percent - a clear indication of better blood glucose control.

Amycretin had already impressed in earlier tests with a weight loss of almost 25 percent. What is new about the current study is that for the first time the drug was used specifically in people with type 2 diabetes. The active ingredient was used both as an injection - in six weekly doses with increasing amounts - and in tablet form with three daily doses.

Source: www.derauktionaer.de

$CAMX (-0,78%)
$NOVO B (+0,04%)

Hello my dears,

For those who are already disappointed with the Danish 🇩🇰 Novo. I would like to remind you once again of the Swedish 🇸🇪 Camurus.